Journal of Pharmaceutics & Drug Delivery ResearchISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Impact of HLA-class I alleles on response to HCV treatment in a cohort of Egyptian patients


Howayda Ezz El Din Gomaa

National Research Centre-Cairo, Egypt

: J Pharm Drug Deliv Res

Abstract


Aims & Background: Extensive allele diversity is observed in HLA associations with response to HCV combined therapy (pegylated interferon+ ribavitin) in different populations. The aim of the study is to assess the frequency and association of certain HLA-class I alleles in Egyptian persons with persistent HCV and others with sustained viral response (SVR). Methods & Materials: The study was a retrospective cohort study that included 246 HCV patients who received combined therapy; 106 cases responded to treatment (SVR) and 140 individuals did not respond to treatment (persistent HCV infection). Both groups are subjected to genotyping for HLA-class I. Results: According to logistic regression analysis, Cw17 was considered as the most predictor allele as it was the highest significant allele (OR=16.70; 95% CI: 2.64–105.58; P = 0.003), whereas the presence of the HLA-B45 and HLA-B27 alleles has a 19.35-fold risk and 15.7 fold risk, respectively of non-response to interferon therapy in chronic HCV patients (OR= 19.35; 95% CI: 1.05–357.24; P=0.04) and (OR= 15.69; 95% CI: 1.179–208.9; P =0.04) can act also as high predictor alleles, and the lowest significant predictor allele was B44 (OR=6.535; 95% CI: 1.55–27.63; P = 0.01). The presence of the HLA-A alleles might have a limited role in prediction for the non-responders, as the A32 was significantly higher among the SVR patients, but, it cannot have a predictor role (OR: 0.161, CI: 0.03–1.056, P=0.049). Conclusion: Cw17, HLA-B45, and HLA-B27 alleles can predict the non-responders to HCV combined therapy.

Biography


Howayda Ezz El Din Gomaa has completed her MD in Clinical and Chemical Pathology from Faculty of Medicine, Cairo University, Egypt and Post-doctoral studies in microbiology, immunology of infectious diseases from the National Research Centre (Egypt). She published more than 30 papers and serves as a reviewer in scientific journals and in the scientific committee of the National Research Centre (Egypt). Presently, she is Professor of Clinical and Chemical Pathology - Clinical and Chemical Pathology Department - NRC-Egypt.

Email: howaydagomaa61@gmail.com

Track Your Manuscript

Awards Nomination

GET THE APP